集成的capecitabine-Temozolomide与放射栓塞用于肝主导的G2 NETs:单个机构回顾性研究的长期结果
Michael C Soulen1,2, Ursina R Teitelbaum3, Rosemarie Mick4
1Neuroendocrine Tumor Program, Division of Interventional Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Michael.soulen@pennmedicine.upenn.edu.
Cardiovascular and interventional radiology
|December 6, 2023
概括
结合capecitabine-temozolomide (CapTem) 和Y90放射栓塞 (TARE) 提供了对2级神经内分泌瘤肝转移的持久控制,与标准治疗相比,显著改善了无进展生存率.
科学领域:
- 医学瘤学 医学瘤学
- 放射学 放射学是一门学科.
- 核医学就是核医学.
背景情况:
- 神经内分泌瘤 (NETs) 是一种异质的瘤群.
- 肝转移在NET中很常见,并显著影响预后.
- 开普西塔-特莫索洛米德 (CapTem) 是一种具有放射敏感性功能的口服化疗方案.
研究的目的:
- 评估将CapTem与Y90跨动脉放射栓塞 (TARE) 结合在患有2级NET肝转移的患者中的疗效和安全性.
- 扩大以前的可行性研究结果,以更大的队列和更长的后续.
主要方法:
- 患者接受了每月一次的CapTem (capecitabine和temozolomide) 周期.
- 用Y90树脂微球TARE注射到主导性肝叶,并对比洛巴病进行了顺序治疗.
- 定期进行临床和成像评估,以监测反应和毒性.
主要成果:
- 在37名患者中,有35人完成了治疗方案.
- 肝脏的客观反应率 (ORR) 为72%,疾病控制率为100%.
- 从CapTemY90开始,中位数无进展生存期 (PFS) 为36个月,中位数总生存期为41个月.
结论:
- 用CapTem和TARE进行化学辐射证明了2级NET肝转移的持久控制.
- 这种综合方法比单独使用栓塞治疗或化疗提供了明显更长的无进展生存期.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...